The Flowr Corporation (TSX-V:FLWR) (OTC:FLWPF) announced Monday that its FlowrRx products are now available for purchase through Shoppers Drug Mart’s online medical cannabis site.

On January 9, the two companies confirmed a sales agreement. Under the pact, Shoppers Drug Mart will be the exclusive direct-to-patient online provider of FlowrRx products. Previously, FlowrRx products were available online to patients registered via Flowr’s website.

Shares in the Toronto-headquartered company climbed nearly 1% to US$5.21 in the OTC Markets, while they were up 1.8% to C$6.94 in Canada. 

The company said the relationship with Shoppers Drug Mart represents a "milestone in the de-stigmatization of medical cannabis."

Shoppers Drug Mart bills itself as the first Canadian retail pharmacy chain to offer a variety of cannabis products to medical cannabis patients, but while product information is available nationally, it can initially only sell medical cannabis to patients in Ontario, through its shoppersdrugmart.ca/cannabis site.

“We’re pleased to provide patients with the high quality and consistent products they seek, now with access to the world class patient care team that Shoppers Drug Mart has assembled,” said Flowr Corp co-CEO Vinay Tolia. “Flowr’s premium medical cannabis is grown in what we believe is the industry’s most advanced Good Manufacturing Practice (GMP)-designed cultivation facility. This relationship is testament to our commitment to ultra-high-quality cannabis cultivation and further solidifies Flowr’s role in Canada’s medical cannabis landscape.”

To order, patients must submit a completed medical document from a healthcare practitioner to Shoppers Drug Mart directly to begin the process.

Medical documents can be dropped off at Shoppers Drug Mart pharmacies in Ontario, provided by mail, or directly by a healthcare practitioner via secure fax.

Specialized advisers from the “Shoppers Cannabis Care team” will then contact the patients, review their medical history, and provide support with online registration and product selection.

Flowr through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. Headquartered in Toronto with a production facility in Kelowna, British Columbia, Flowr builds and operates large-scale, cultivation facilities utilizing its own patented growing systems. When fully completed, Flowr’s Kelowna campus is expected to produce over 50,000 kg of premium flower annually.

Flowr is expanding globally in Portugal and Australia, and recently broke ground on a 50,000 square feet R&D facility in partnership with Hawthorne, a subsidiary of Scotts Miracle Gro.